Keywords: aromasin, prolongs, breast, cancer, survival, new, data

Aromasin prolongs breast cancer survival

Article | 29 March 2004

New data supporting Pfizer's steroidal aromatase inhibitor Aromasin (exemestane) have been presented at the 4th European Breast Cancer Conference by ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Go to company listing

Related Drugs

Aromasin

Exemestane

Anastrozole

Arimidex

Endometrin

Go to drug listing